Toxicological Research

  • 제41권2호
  • /
  • Pages.105-121
  • /
  • 2025
  • /
  • 1976-8257(pISSN)
  • /
  • 2234-2753(eISSN)
한국독성학회 (Korean Society of Toxicology & Korea Environmental Mutagen Society)
권호 표지
DOI QR코드

DOI QR Code

Current hPSC‑derived liver organoids for toxicity testing: Cytochrome P450 enzymes and drug metabolism

  • Hyemin Kim ( Division of Advanced Predictive Research, Korea Institute of Toxicology) ;
  • Han‑Jin Park ( Division of Advanced Predictive Research, Korea Institute of Toxicology)
  • 투고 : 2024.10.13
  • 심사 : 2024.12.11
  • 발행 : 2025.03.15
⟨ 이전 논문 다음 논문 ⟩

초록

Drug-induced hepatotoxicity is the leading cause of attrition of drug candidates and withdrawal of marketed drugs owing to safety concerns. In most hepatotoxicity cases, the parent drugs are metabolized by cytochrome P450 (CYP) enzymes, generating reactive metabolites that bind to intracellular organelles and proteins, ultimately causing hepatocellular damage. A major limitation of animal models, which are widely used for toxicity assessment, is the discrepancy in CYP-mediated drug metabolism and toxicological outcomes owing to species differences between humans and animals. Two-dimensional (2D) hepatocytes were first developed as a promising alternative model using human pluripotent stem cells (hPSCs). However, their CYP expression was similar to that of the fetal liver, and they lacked CYP-mediated hepatic metabolism. CYP expression in hPSC-derived hepatic models is closely correlated with liver maturity. Therefore, liver organoids that are more mature than hPSC-derived hepatic models and mimic the structure and physiological functions of the human liver have emerged as new alternatives. In this review, we explored the role and essentiality of CYPs in human hepatotoxicity, their expression, and epigenetic regulation in hPSC-derived hepatocytes and liver organoids, as well as the current state of liver organoid technology in terms of CYP expression and activity, drug metabolism, and toxicity. We also discussed the current challenges and future directions for the practical use of liver organoids. In conclusion, we highlight the importance of methods and metrics for accurately assessing CYP expression and activity in liver organoids to enable the development of feasible models that reproduce hepatotoxicity in humans.

키워드

과제정보

This work was supported by the Korea Institute of Toxicology [Grant No. 2710008763] and a National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIT) [Grant No. RS-2023–00210505].

참고문헌

  1. Serras AS, Rodrigues JS, Cipriano M, Rodrigues AV, Oliveira NG, Miranda JP (2021) A critical perspective on 3D liver models for drug metabolism and toxicology studies. Front Cell Dev Biol 9:626805. https://doi.org/10.3389/fcell.2021.626805
  2. Onakpoya IJ, Heneghan CJ, Aronson JK (2016) Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med 14:10. https://doi.org/10.1186/s12916-016-0553-2
  3. Siramshetty VB, Nickel J, Omieczynski C, Gohlke BO, Drwal MN, Preissner R (2016) WITHDRAWN—a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44:D1080–D1086. https://doi.org/10.1093/nar/gkv1192
  4. Zhang X, Jiang T, Chen D, Wang Q, Zhang LW (2020) Three-dimensional liver models: state of the art and their application for hepatotoxicity evaluation. Crit Rev Toxicol 50:279–309. https://doi.org/10.1080/10408444.2020.1756219
  5. Steigerwald K, Merl S, Kastrati A, Wieczorek A, Vorpahl M, Mannhold R, Vogeser M, Hausleiter J, Joner M, Schomig A, Wessely R (2009) The pre-clinical assessment of rapamycin-eluting, durable polymer-free stent coating concepts. Biomaterials 30:632–637. https://doi.org/10.1016/j.biomaterials.2008.10.005
  6. van Tonder JJVS, Gulumian M (2013) Pre-clinical assessment of the potential intrinsic hepatotoxicity of candidate drugs. In: Gowder S (ed) New insights into toxicity and drug testing. IntechOpen. https://doi.org/10.5772/54792
  7. Van Norman GA (2019) Limitations of Animal Studies for Predicting Toxicity in Clinical Trials: Is it Time to Rethink Our Current Approach? JACC Basic Transl Sci 4:845–854. https://doi.org/10.1016/j.jacbts.2019.10.008
  8. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67. https://doi.org/10.1006/rtph.2000.1399
  9. Shanks N, Greek R, Greek J (2009) Are animal models predictive for humans? Philos Ethics Humanit Med 4:2. https://doi.org/10.1186/1747-5341-4-2
  10. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo YY, Masek M, Michie SA, Glenn J, Peltz G (2014) Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med 11:e1001628. https://doi.org/10.1371/journal.pmed.1001628
  11. Martignoni M, Groothuis GM, de Kanter R (2006) Species diferences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2:875–894. https://doi.org/10.1517/17425255.2.6.875
  12. Ruoss M, Vosough M, Konigsrainer A, Nadalin S, Wagner S, Sajadian S, Huber D, Heydari Z, Ehnert S, Hengstler JG, Nussler AK (2020) Towards improved hepatocyte cultures: progress and limitations. Food Chem Toxicol 138:111188. https://doi.org/10.1016/j.fct.2020.111188
  13. Nelson DR, Zeldin DC, Hofman SM, Maltais LJ, Wain HM, Nebert DW (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1–18. https://doi.org/10.1097/00008571-200401000-00001
  14. Cox CR, Lynch S, Goldring C, Sharma P (2020) Current perspective: 3D spheroid models utilizing human-based cells for investigating metabolism-dependent drug-induced liver injury. Front Med Technol 2:611913. https://doi.org/10.3389/fmedt.2020.611913
  15. Yang S, Ooka M, Margolis RJ, Xia M (2023) Liver three-dimensional cellular models for high-throughput chemical testing. Cell Rep Methods 3:100432. https://doi.org/10.1016/j.crmeth.2023.100432
  16. Castell JV, Jover R, Martinez-Jimenez CP, Gomez-Lechon MJ (2006) Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin Drug Metab Toxicol 2:183–212. https://doi.org/10.1517/17425255.2.2.183
  17. Wong N, Lai P, Pang E, Leung TW, Lau JW, Johnson PJ (2000) A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping. Hepatology 32:1060–1068. https://doi.org/10.1053/jhep.2000.19349
  18. Slany A, Haudek VJ, Zwickl H, Gundacker NC, Grusch M, Weiss TS, Seir K, Rodgarkia-Dara C, Hellerbrand C, Gerner C (2010) Cell characterization by proteome profling applied to primary hepatocytes and hepatocyte cell lines Hep-G2 and Hep-3B. J Proteome Res 9:6–21. https://doi.org/10.1021/pr900057t
  19. Liu S, Cheng C, Zhu L, Zhao T, Wang Z, Yi X, Yan F, Wang X, Li C, Cui T, Yang B (2024) Liver organoids: updates on generation strategies and biomedical applications. Stem Cell Res Ther 15:244. https://doi.org/10.1186/s13287-024-03865-3
  20. Marsee A, Roos FJM, Verstegen MMA, Consortium HPBO, Gehart H, de Koning E, Lemaigre F, Forbes SJ, Peng WC, Huch M, Takebe T, Vallier L, Clevers H, van der Laan LJW, Spee B (2021) Building consensus on defnition and nomenclature of hepatic, pancreatic, and biliary organoids. Cell Stem Cell 28:816–832. https://doi.org/10.1016/j.stem.2021.04.005
  21. Mun SJ, Ryu JS, Lee MO, Son YS, Oh SJ, Cho HS, Son MY, Kim DS, Kim SJ, Yoo HJ, Lee HJ, Kim J, Jung CR, Chung KS, Son MJ (2019) Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. J Hepatol 71:970–985. https://doi.org/10.1016/j.jhep.2019.06.030
  22. Wang S, Wang X, Tan Z, Su Y, Liu J, Chang M, Yan F, Chen J, Chen T, Li C, Hu J, Wang Y (2019) Human ESC-derived expandable hepatic organoids enable therapeutic liver repopulation and pathophysiological modeling of alcoholic liver injury. Cell Res 29:1009–1026. https://doi.org/10.1038/s41422-019-0242-8
  23. Kim H, Im I, Jeon JS, Kang EH, Lee HA, Jo S, Kim JW, Woo DH, Choi YJ, Kim HJ, Han JS, Lee BS, Kim JH, Kim SK, Park HJ (2022) Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment. Biomaterials 286:121575. https://doi.org/10.1016/j.biomaterials.2022.121575
  24. Prior N, Inacio P, Huch M (2019) Liver organoids: from basic research to therapeutic applications. Gut 68:2228–2237. https://doi.org/10.1136/gutjnl-2019-319256
  25. Li Y, Cui Y, Hart SN, Klaassen CD, Zhong XB (2009) Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. Mol Pharmacol 75:1171–1179. https://doi.org/10.1124/mol.108.052993
  26. He H, Nie YL, Li JF, Meng XG, Yang WH, Chen YL, Wang SJ, Ma X, Kan QC, Zhang LR (2016) Developmental regulation of CYP3A4 and CYP3A7 in Chinese Han population. Drug Metab Pharmacokinet 31:433–444. https://doi.org/10.1016/j.dmpk.2016.08.008
  27. Vyhlidal CA, Bi C, Ye SQ, Leeder JS (2016) Dynamics of cytosine methylation in the proximal promoters of CYP3A4 and CYP3A7 in pediatric and prenatal livers. Drug Metab Dispos 44:1020–1026. https://doi.org/10.1124/dmd.115.068726
  28. Jin J, Zhong XB (2023) Epigenetic mechanisms contribute to intraindividual variations of drug metabolism mediated by cytochrome P450 enzymes. Drug Metab Dispos 51:672–684. https://doi.org/10.1124/dmd.122.001007
  29. Benedetti MS, Whomsley R, Poggesi I, Cawello W, Mathy FX, Delporte ML, Papeleu P, Watelet JB (2009) Drug metabolism and pharmacokinetics. Drug Metab Rev 41:344–390. https://doi.org/10.1080/10837450902891295
  30. Almazroo OA, Miah MK, Venkataramanan R (2017) Drug Metabolism in the Liver. Clin Liver Dis 21:1–20. https://doi.org/10.1016/j.cld.2016.08.001
  31. Iyanagi T (2007) Molecular mechanism of phase I and phase II drug-metabolizing enzymes: implications for detoxifcation. Int Rev Cytol 260:35–112. https://doi.org/10.1016/S0074-7696(06)60002-8
  32. Grillo MP (2011) Bioactivation by Phase-II-enzyme-catalyzed conjugation of xenobiotics. In: Encyclopedia of drug metabolism and interactions. https://doi.org/10.1002/9780470921920.edm074
  33. Brodie BB, Reid WD, Cho AK, Sipes G, Krishna G, Gillette JR (1971) Possible mechanism of liver necrosis caused by aromatic organic compounds. Proc Natl Acad Sci U S A 68:160–164. https://doi.org/10.1073/pnas.68.1.160
  34. Manikandan P, Nagini S (2018) Cytochrome P450 structure, function and clinical signifcance: a review. Curr Drug Targets 19:38–54. https://doi.org/10.2174/1389450118666170125144557
  35. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141. https://doi.org/10.1016/j.pharmthera.2012.12.007
  36. Rendic S, Guengerich FP (2012) Contributions of human enzymes in carcinogen metabolism. Chem Res Toxicol 25:1316–1383. https://doi.org/10.1021/tx300132k
  37. Slaughter RL, Edwards DJ (1995) Recent advances: the cytochrome P450 enzymes. Ann Pharmacother 29:619–624. https://doi.org/10.1177/106002809502900612
  38. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211–2221. https://doi.org/10.1056/NEJMra032424
  39. Hsu MH, Savas U, Lasker JM, Johnson EF (2011) Genistein, resveratrol, and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside induce cytochrome P450 4F2 expression through an AMP-activated protein kinase-dependent pathway. J Pharmacol Exp Ther 337:125–136. https://doi.org/10.1124/jpet.110.175851
  40. Edson KZ, Rettie AE (2013) CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid omega-hydroxylase activities. Curr Top Med Chem 13:1429–1440. https://doi.org/10.2174/15680266113139990110
  41. Seguin RP, Herron JM, Lopez VA, Dempsey JL, Xu L (2019) Metabolism of benzalkonium chlorides by human hepatic cytochromes P450. Chem Res Toxicol 32:2466–2478. https://doi.org/10.1021/acs.chemrestox.9b00293
  42. Miller EC, Miller JA (1952) In vivo combinations between carcinogens and tissue constituents and their possible role in carcinogenesis. Cancer Res 12:547–556
  43. Gillette JR, Mitchell JR, Brodie BB (1974) Biochemical mechanisms of drug toxicity. Annu Rev Pharmacol 14:271–288. https://doi.org/10.1146/annurev.pa.14.040174.001415
  44. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45:177–202. https://doi.org/10.1146/annurev.pharmtox.45.120403.100058
  45. Lynch T, Price A (2007) The efect of cytochrome P450 metabolism on drug response, interactions, and adverse efects. Am Fam Physician 76:391–396
  46. Esteves F, Ruef J, Kranendonk M (2021) The central role of cytochrome P450 in xenobiotic metabolism—a brief review on a fascinating enzyme family. J Xenobiot 11:94–114. https://doi.org/10.3390/jox11030007
  47. Testa B, Kraemer SD (2009) The biochemistry of drug metabolism–an introduction: part 5. Metabolism and bioactivity. Chem Biodivers 6:591–684. https://doi.org/10.1002/cbdv.200900022
  48. Thompson RA, Isin EM, Ogese MO, Mettetal JT, Williams DP (2016) Reactive metabolites: current and emerging risk and hazard assessments. Chem Res Toxicol 29:505–533. https://doi.org/10.1021/acs.chemrestox.5b00410
  49. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, Lambert C, Laverty HG, Naisbitt DJ, Nelson S (2011) Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discovery 10:292–306. https://doi.org/10.1038/nrd3408
  50. Thomson JA, Itskovitz-Eldor J, Shapiro SS, Waknitz MA, Swiergiel JJ, Marshall VS, Jones JM (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147. https://doi.org/10.1126/science.282.5391.1145
  51. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872. https://doi.org/10.1016/j.cell.2007.11.019
  52. Natale A, Vanmol K, Arslan A, Van Vlierberghe S, Dubruel P, Van Erps J, Thienpont H, Buzgo M, Boeckmans J, De Kock J, Vanhaecke T, Rogiers V, Rodrigues RM (2019) Technological advancements for the development of stem cell-based models for hepatotoxicity testing. Arch Toxicol 93:1789–1805. https://doi.org/10.1007/s00204-019-02465-y
  53. Cai J, Zhao Y, Liu Y, Ye F, Song Z, Qin H, Meng S, Chen Y, Zhou R, Song X, Guo Y, Ding M, Deng H (2007) Directed diferentiation of human embryonic stem cells into functional hepatic cells. Hepatology 45:1229–1239. https://doi.org/10.1002/hep.21582
  54. Ek M, Soderdahl T, Kuppers-Munther B, Edsbagge J, Andersson TB, Bjorquist P, Cotgreave I, Jernstrom B, Ingelman-Sundberg M, Johansson I (2007) Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 74:496–503. https://doi.org/10.1016/j.bcp.2007.05.009
  55. Hay DC, Zhao D, Ross A, Mandalam R, Lebkowski J, Cui W (2007) Direct diferentiation of human embryonic stem cells to hepatocyte-like cells exhibiting functional activities. Cloning Stem Cells 9:51–62. https://doi.org/10.1089/clo.2006.0045
  56. Hay DC, Zhao D, Fletcher J, Hewitt ZA, McLean D, Urruticoechea-Uriguen A, Black JR, Elcombe C, Ross JA, Wolf R, Cui W (2008) Efcient diferentiation of hepatocytes from human embryonic stem cells exhibiting markers recapitulating liver development in vivo. Stem Cells 26:894–902. https://doi.org/10.1634/stemcells.2007-0718
  57. Moore RN, Moghe PV (2009) Expedited growth factor-mediated specifcation of human embryonic stem cells toward the hepatic lineage. Stem Cell Res 3:51–62. https://doi.org/10.1016/j.scr.2009.04.004
  58. Zhao D, Chen S, Cai J, Guo Y, Song Z, Che J, Liu C, Wu C, Ding M, Deng H (2009) Derivation and characterization of hepatic progenitor cells from human embryonic stem cells. PLoS One 4:e6468. https://doi.org/10.1371/journal.pone.0006468
  59. Si-Tayeb K, Lemaigre FP, Duncan SA (2010) Organogenesis and development of the liver. Dev Cell 18:175–189. https://doi.org/10.1016/j.devcel.2010.01.011
  60. Baxter MA, Rowe C, Alder J, Harrison S, Hanley KP, Park BK, Kitteringham NR, Goldring CE, Hanley NA (2010) Generating hepatic cell lineages from pluripotent stem cells for drug toxicity screening. Stem Cell Res 5:4–22. https://doi.org/10.1016/j.scr.2010.02.002
  61. Baxter M, Withey S, Harrison S, Segeritz CP, Zhang F, Atkinson-Dell R, Rowe C, Gerrard DT, Sison-Young R, Jenkins R, Henry J, Berry AA, Mohamet L, Best M, Fenwick SW, Malik H, Kitteringham NR, Goldring CE, Piper Hanley K, Vallier L, Hanley NA (2015) Phenotypic and functional analyses show stem cellderived hepatocyte-like cells better mimic fetal rather than adult hepatocytes. J Hepatol 62:581–589. https://doi.org/10.1016/j.jhep.2014.10.016
  62. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T (1997) Expression of CYP3A in the human liver–evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625–634. https://doi.org/10.1111/j.1432-1033.1997.00625.x
  63. Hines RN (2007) Ontogeny of human hepatic cytochromes P450. J Biochem Mol Toxicol 21:169–175. https://doi.org/10.1002/jbt.20179
  64. Gao X, Liu Y (2017) A transcriptomic study suggesting human iPSC-derived hepatocytes potentially ofer a better in vitro model of hepatotoxicity than most hepatoma cell lines. Cell Biol Toxicol 33:407–421. https://doi.org/10.1007/s10565-017-9383-z
  65. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN (2004) Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308:965–974. https://doi.org/10.1124/jpet.103.060137
  66. Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, Hines RN (2008) Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 36:1587–1593. https://doi.org/10.1124/dmd.108.021873
  67. Sadler NC, Nandhikonda P, Webb-Robertson BJ, Ansong C, Anderson LN, Smith JN, Corley RA, Wright AT (2016) Hepatic ṁytochrome P450 activity, abundance, and expression throughout human development. Drug Metab Dispos 44:984–991. https://doi.org/10.1124/dmd.115.068593
  68. Moore LD, Le T, Fan G (2013) DNA methylation and its basic function. Neuropsychopharmacology 38:23–38. https://doi.org/10.1038/npp.2012.112
  69. Berger SL (2002) Histone modifcations in transcriptional regulation. Curr Opin Genet Dev 12:142–148. https://doi.org/10.1016/s0959-437x(02)00279-4
  70. Lawrence M, Daujat S, Schneider R (2016) Lateral thinking: how histone modifcations regulate gene expression. Trends Genet 32:42–56. https://doi.org/10.1016/j.tig.2015.10.007
  71. Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, Ingelman-Sundberg M (2012) DNA methylation dynamics in the hepatic CYP3A4 gene promoter. Biochimie 94:2338–2344. https://doi.org/10.1016/j.biochi.2012.07.013
  72. Habano W, Kawamura K, Iizuka N, Terashima J, Sugai T, Ozawa S (2015) Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes. Clin Epigenetics 7:105. https://doi.org/10.1186/s13148-015-0136-7
  73. Kim HM, Kim JW, Choi Y, Chun HS, Im I, Han YM, Song CW, Yoon S, Park HJ (2016) Xeno-sensing activity of the aryl hydrocarbon receptor in human pluripotent stem cell-derived hepatocyte-like cells. Sci Rep 6:21684. https://doi.org/10.1038/srep21684
  74. Betts S, Bjorkhem-Bergman L, Rane A, Ekstrom L (2015) Expression of CYP3A4 and CYP3A7 in human foetal tissues and its correlation with nuclear receptors. Basic Clin Pharmacol Toxicol 117:261–266. https://doi.org/10.1111/bcpt.12392
  75. Park HJ, Choi YJ, Kim JW, Chun HS, Im I, Yoon S, Han YM, Song CW, Kim H (2015) Diferences in the epigenetic regulation of cytochrome P450 genes between human embryonic stem cell-derived hepatocytes and primary hepatocytes. PLoS One 10:e0132992. https://doi.org/10.1371/journal.pone.0132992
  76. Gao Y, Zhang X, Zhang L, Cen J, Ni X, Liao X, Yang C, Li Y, Chen X, Zhang Z, Shu Y, Cheng X, Hay DC, Lai D, Pan G, Wei G, Hui L (2017) Distinct gene expression and epigenetic signatures in hepatocyte-like cells produced by diferent strategies from the same donor. Stem Cell Reports 9:1813–1824. https://doi.org/10.1016/j.stemcr.2017.10.019
  77. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA (2010) Highly efcient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51:297–305. https://doi.org/10.1002/hep.23354
  78. Ogawa S, Surapisitchat J, Virtanen C, Ogawa M, Niapour M, Sugamori KS, Wang S, Tamblyn L, Guillemette C, Hofmann E, Zhao B, Strom S, Laposa RR, Tyndale RF, Grant DM, Keller G (2013) Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development 140:3285–3296. https://doi.org/10.1242/dev.090266
  79. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, Tachibana M, Kanda K, Hayakawa T, Furue MK, Mizuguchi H (2013) 3D spheroid culture of hESC/hiPSC-derived hepatocyte-like cells for drug toxicity testing. Biomaterials 34:1781–1789. https://doi.org/10.1016/j.biomaterials.2012.11.029
  80. Sirenko O, Hancock MK, Hesley J, Hong D, Cohen A, Gentry J, Carlson CB, Mann DA (2016) Phenotypic characterization of toxic compound efects on liver spheroids derived from iPSC using confocal imaging and three-dimensional image analysis. Assay Drug Dev Technol 14:381–394. https://doi.org/10.1089/adt.2016.729
  81. Meier F, Freyer N, Brzeszczynska J, Knospel F, Armstrong L, Lako M, Greuel S, Damm G, Ludwig-Schwellinger E, Deschl U, Ross JA, Beilmann M, Zeilinger K (2017) Hepatic diferentiation of human iPSCs in diferent 3D models: a comparative study. Int J Mol Med 40:1759–1771. https://doi.org/10.3892/ijmm.2017.3190
  82. Rashidi H, Luu NT, Alwahsh SM, Ginai M, Alhaque S, Dong H, Tomaz RA, Vernay B, Vigneswara V, Hallett JM, Chandrashekran A, Dhawan A, Vallier L, Bradley M, Callanan A, Forbes SJ, Newsome PN, Hay DC (2018) 3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo. Arch Toxicol 92:3117–3129. https://doi.org/10.1007/s00204-018-2280-2
  83. Chen S, Wang J, Ren H, Liu Y, Xiang C, Li C, Lu S, Shi Y, Deng H, Shi X (2020) Hepatic spheroids derived from human induced pluripotent stem cells in bio-artifcial liver rescue porcine acute liver failure. Cell Res 30:95–97. https://doi.org/10.1038/s41422-019-0261-5
  84. Lee G, Kim H, Park JY, Kim G, Han J, Chung S, Yang JH, Jeon JS, Woo DH, Han C, Kim SK, Park HJ, Kim JH (2021) Generation of uniform liver spheroids from human pluripotent stem cells for imaging-based drug toxicity analysis. Biomaterials 269:120529. https://doi.org/10.1016/j.biomaterials.2020.120529
  85. Qosa H, Ribeiro AJS, Hartman NR, Volpe DA (2021) Characterization of a commercially available line of iPSC hepatocytes as models of hepatocyte function and toxicity for regulatory purposes. J Pharmacol Toxicol Methods 110:107083. https://doi.org/10.1016/j.vascn.2021.107083
  86. Camp JG, Sekine K, Gerber T, Loefer-Wirth H, Binder H, Gac M, Kanton S, Kageyama J, Damm G, Seehofer D, Belicova L, Bickle M, Barsacchi R, Okuda R, Yoshizawa E, Kimura M, Ayabe H, Taniguchi H, Takebe T, Treutlein B (2017) Multilineage communication regulates human liver bud development from pluripotency. Nature 546:533–538. https://doi.org/10.1038/nature22796
  87. Ma H, de Zwaan E, Guo YE, Cejas P, Thiru P, van de Bunt M, Jeppesen JF, Syamala S, Dall'Agnese A, Abraham BJ, Fu D, Garrett-Engele C, Lee TI, Long HW, Grifth LG, Young RA, Jaenisch R (2022) The nuclear receptor THRB facilitates differentiation of human PSCs into more mature hepatocytes. Cell Stem Cell 29:e711. https://doi.org/10.1016/j.stem.2022.03.015
  88. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H (2013) Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature 499:481–484. https://doi.org/10.1038/nature12271
  89. Guan Y, Xu D, Garfn PM, Ehmer U, Hurwitz M, Enns G, Michie S, Wu M, Zheng M, Nishimura T, Sage J, Peltz G (2017) Human hepatic organoids for the analysis of human genetic diseases. JCI Insight 2:e94954. https://doi.org/10.1172/jci.insight.94954
  90. Takebe T, Sekine K, Kimura M, Yoshizawa E, Ayano S, Koido M, Funayama S, Nakanishi N, Hisai T, Kobayashi T, Kasai T, Kitada R, Mori A, Ayabe H, Ejiri Y, Amimoto N, Yamazaki Y, Ogawa S, Ishikawa M, Kiyota Y, Sato Y, Nozawa K, Okamoto S, Ueno Y, Taniguchi H (2017) Massive and reproducible production of liver buds entirely from human pluripotent stem cells. Cell Rep 21:2661–2670. https://doi.org/10.1016/j.celrep.2017.11.005
  91. Akbari S, Sevinc GG, Ersoy N, Basak O, Kaplan K, Sevinc K, Ozel E, Sengun B, Enustun E, Ozcimen B, Bagriyanik A, Arslan N, Onder TT, Erdal E (2019) Robust, long-term culture of endoderm-derived hepatic organoids for disease modeling. Stem Cell Reports 13:627–641. https://doi.org/10.1016/j.stemcr.2019.08.007
  92. Koike H, Iwasawa K, Ouchi R, Maezawa M, Giesbrecht K, Saiki N, Ferguson A, Kimura M, Thompson WL, Wells JM, Zorn AM, Takebe T (2019) Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary. Nature 574:112–116. https://doi.org/10.1038/s41586-019-1598-0
  93. Wu F, Wu D, Ren Y, Huang Y, Feng B, Zhao N, Zhang T, Chen X, Chen S, Xu A (2019) Generation of hepatobiliary organoids from human induced pluripotent stem cells. J Hepatol 70:1145–1158. https://doi.org/10.1016/j.jhep.2018.12.028
  94. Nishimura T, Hu Y, Wu M, Pham E, Suemizu H, Elazar M, Liu M, Idilman R, Yurdaydin C, Angus P, Stedman C, Murphy B, Glenn J, Nakamura M, Nomura T, Chen Y, Zheng M, Fitch WL, Peltz G (2013) Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J Pharmacol Exp Ther 344:388–396. https://doi.org/10.1124/jpet.112.198697
  95. Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernandez N, Ibanez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK, International Drug-Induced Liver Injury Consortium D-ILINI, International Serious Adverse Events C (2017) Association of liver injury from specifc drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. Gastroenterology 152:1078–1089. https://doi.org/10.1053/j.gastro.2016.12.016
  96. Koido M, Kawakami E, Fukumura J, Noguchi Y, Ohori M, Nio Y, Nicoletti P, Aithal GP, Daly AK, Watkins PB, Anayama H, Dragan Y, Shinozawa T, Takebe T (2020) Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nat Med 26:1541–1548. https://doi.org/10.1038/s41591-020-1023-0
  97. Ramli MNB, Lim YS, Koe CT, Demircioglu D, Tng W, Gonzales KAU, Tan CP, Szczerbinska I, Liang H, Soe EL, Lu Z, Ariyachet C, Yu KM, Koh SH, Yaw LP, Jumat NHB, Lim JSY, Wright G, Shabbir A, Dan YY, Ng HH, Chan YS (2020) Human pluripotent stem cell-derived organoids as models of liver disease. Gastroenterology 159:e1412. https://doi.org/10.1053/j.gastro.2020.06.010
  98. Shinozawa T, Kimura M, Cai Y, Saiki N, Yoneyama Y, Ouchi R, Koike H, Maezawa M, Zhang RR, Dunn A, Ferguson A, Togo S, Lewis K, Thompson WL, Asai A, Takebe T (2021) High-fdelity drug-induced liver injury screen using human pluripotent stem cell-derived organoids. Gastroenterology 160:e810. https://doi.org/10.1053/j.gastro.2020.10.002
  99. Dragovic S, Vermeulen NP, Gerets HH, Hewitt PG, Ingelman-Sundberg M, Park BK, Juhila S, Snoeys J, Weaver RJ (2016) Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man. Arch Toxicol 90:2979–3003. https://doi.org/10.1007/s00204-016-1845-1
  100. Zhang CJ, Meyer SR, O'Meara MJ, Huang S, Capeling MM, Ferrer-Torres D, Childs CJ, Spence JR, Fontana RJ, Sexton JZ (2023) A human liver organoid screening platform for DILI risk prediction. J Hepatol 78:998–1006. https://doi.org/10.1016/j.jhep.2023.01.019
  101. Ouchi R, Togo S, Kimura M, Shinozawa T, Koido M, Koike H, Thompson W, Karns RA, Mayhew CN, McGrath PS, McCauley HA, Zhang RR, Lewis K, Hakozaki S, Ferguson A, Saiki N, Yoneyama Y, Takeuchi I, Mabuchi Y, Akazawa C, Yoshikawa HY, Wells JM, Takebe T (2019) Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids. Cell Metab 30:e376. https://doi.org/10.1016/j.cmet.2019.05.007
  102. Shin W, Wu A, Min S, Shin YC, Fleming RYD, Eckhardt SG, Kim HJ (2020) Spatiotemporal gradient and instability of Wnt induce heterogeneous growth and diferentiation of human intestinal organoids. iScience 23:101372. https://doi.org/10.1016/j.isci.2020.101372
  103. Gu R, Liang A, Liao G, To I, Shehu A, Ma X (2022) Roles of cofactors in drug-induced liver injury: drug metabolism and beyond. Drug Metab Dispos 50:646–654. https://doi.org/10.1124/dmd.121.000457
  104. Seo W, Jeong WI (2016) Hepatic non-parenchymal cells: Master regulators of alcoholic liver disease? World J Gastroenterol 22:1348–1356. https://doi.org/10.3748/wjg.v22.i4.1348
  105. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Bottger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gomez-Lechon MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Haussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhutter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stober R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and nonparenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530. https://doi.org/10.1007/s00204-013-1078-5
  106. Bell CC, Chouhan B, Andersson LC, Andersson H, Dear JW, Williams DP, Soderberg M (2020) Functionality of primary hepatic non-parenchymal cells in a 3D spheroid model and contribution to acetaminophen hepatotoxicity. Arch Toxicol 94:1251–1263. https://doi.org/10.1007/s00204-020-02682-w
  107. Laskin DL, Pilaro AM (1986) Potential role of activated macrophages in acetaminophen hepatotoxicity. I. Isolation and characterization of activated macrophages from rat liver. Toxicol Appl Pharmacol 86:204–215. https://doi.org/10.1016/0041-008x(86)90051-7
  108. Michael SL, Pumford NR, Mayeux PR, Niesman MR, Hinson JA (1999) Pretreatment of mice with macrophage inactivators decreases acetaminophen hepatotoxicity and the formation of reactive oxygen and nitrogen species. Hepatology 30:186–195. https://doi.org/10.1002/hep.510300104
  109. Lee J, Gil D, Park H, Lee Y, Mun SJ, Shin Y, Jo E, Windisch MP, Kim JH, Son MJ (2024) A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression. Hepatology 80:186–201. https://doi.org/10.1097/HEP.0000000000000683
  110. Jo S, Park SB, Kim H, Im I, Noh H, Kim EM, Kim KY, Oelgeschlager M, Kim JH, Park HJ (2024) hiPSC-derived macrophages improve drug sensitivity and selectivity in a macrophage-incorporating organoid culture model. Biofabrication 16:035021. https://doi.org/10.1088/1758-5090/ad4c0a
  111. Moon HR, Mun SJ, Kim TH, Kim H, Kang D, Kim S, Shin JH, Choi D, Ahn SJ, Son MJ (2024) Guidelines for manufacturing and application of organoids: liver. Int J Stem Cells 17:120–129. https://doi.org/10.15283/ijsc24044
  112. Pillai VC, Strom SC, Caritis SN, Venkataramanan R (2013) A sensitive and specifc CYP cocktail assay for the simultaneous assessment of human cytochrome P450 activities in primary cultures of human hepatocytes using LC-MS/MS. J Pharm Biomed Anal 74:126–132. https://doi.org/10.1016/j.jpba.2012.10.016
  113. Jiang F, Zhang C, Lu Z, Liu J, Liu P, Huang M, Zhong G (2022) Simultaneous absolute protein quantifcation of seven cytochrome P450 isoforms in rat liver microsomes by LC-MS/MS-based isotope internal standard method. Front Pharmacol 13:906027. https://doi.org/10.3389/fphar.2022.906027
  114. Trentesaux C, Yamada T, Klein OD, Lim WA (2023) Harnessing synthetic biology to engineer organoids and tissues. Cell Stem Cell 30:10–19. https://doi.org/10.1016/j.stem.2022.12.013
  115. Tamargo-Rubio I, Simpson AB, Hoogerland JA, Fu J (2023) Human induced pluripotent stem cell-derived liver-on-a-chip for studying drug metabolism: the challenge of the cytochrome P450 family. Front Pharmacol 14:1223108. https://doi.org/10.3389/fphar.2023.1223108
  116. Zhao YSL, Okhovatian S, Liu C, Lu RXZ, Lai BFL, Wu Q, Kieda J, Cheung K, Rajasekar S, Jozani K, Zhang B, Radisic M (2024) Integrating organoids and organ-on-a-chip devices. Nat Rev Bioeng 2:588–608. https://doi.org/10.1038/s44222-024-00207-z
  117. Oleaga C, Riu A, Rothemund S, Lavado A, McAleer CW, Long CJ, Persaud K, Narasimhan NS, Tran M, Roles J, Carmona-Moran CA, Sasserath T, Elbrecht DH, Kumanchik L, Bridges LR, Martin C, Schnepper MT, Ekman G, Jackson M, Wang YI, Note R, Langer J, Teissier S, Hickman JJ (2018) Investigation of the efect of hepatic metabolism on of-target cardiotoxicity in a multi-organ human-on-a-chip system. Biomaterials 182:176–190. https://doi.org/10.1016/j.biomaterials.2018.07.062
  118. Vinken M (2024) Adverse outcome pathway networks as the basis for the development of new approach methodologies: liver toxicity as a case study. Curr Opin Toxicol 40:100504. https://doi.org/10.1016/j.cotox.2024.100504